Altavant Sciences, a clinical-stage biopharmaceutical company, completed the acquisition of Onspira Therapeutics, a private drug development company. Financial terms were not disclosed. This acquisition expands Altavant's pipeline to include OSP-101, a novel inhaled interleukin-1 receptor antagonist with orphan drug designation from the US Food and Drug Administration. "I am proud of the achievements of the entire Onspira Therapeutics team as we have progressed the OSP-101 program. We have been impressed by the talented and experienced professionals at Altavant, and we are confident that they are the right team to develop OSP-101 for the treatment of post-lung transplant BOS. This is an important program to bring forward for the benefit of lung transplant patients, and we believe Altavant is well-positioned to achieve this goal," Brian Lortie, Onspira Therapeutics Chief Executive Officer.